DB
SUPN icon

Dmitry Balyasny’s Supernus Pharmaceuticals SUPN Stock Holding History

Dmitry Balyasny’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.99M Buy
85,756
+79,018
+1,173% +$3.8M 0.01% 1478
2026
Q1 		$348K Buy
+6,738
New +$343K ﹤0.01% 2506
2022
Q3 		– Sell
-23,643
Closed -$684K – 3248
2022
Q2 		$684K Sell
23,643
-123,826
-84% -$3.55M ﹤0.01% 1891
2022
Q1 		$4.77M Buy
+147,469
New +$4.52M 0.02% 972
2020
Q3 		– Sell
-18,475
Closed -$439K – 1586
2020
Q2 		$439K Buy
18,475
+1,759
+11% +$38.9K ﹤0.01% 940
2020
Q1 		$301K Sell
16,716
-604
-3% -$12.7K ﹤0.01% 991
2019
Q4 		$411K Buy
+17,320
New +$421K ﹤0.01% 1026
2018
Q3 		– Sell
-4,024
Closed -$241K – 2022
2018
Q2 		$241K Sell
4,024
-1,375
-25% -$71.2K ﹤0.01% 1585
2018
Q1 		$247K Buy
+5,399
New +$225K ﹤0.01% 1685
2017
Q4 		– Sell
-145,625
Closed -$5.83M – 2299
2017
Q3 		$5.83M Buy
145,625
+140,836
+2,941% +$6.09M 0.02% 662
2017
Q2 		$206K Buy
+4,789
New +$170K ﹤0.01% 1377
2016
Q4 		– Sell
-110,847
Closed -$2.74M – 1477
2016
Q3 		$2.74M Buy
+110,847
New +$2.51M 0.02% 586

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Dmitry Balyasny's SUPN Position: Q2 2026 in Review

Dmitry Balyasny increased its Supernus Pharmaceuticals (SUPN) stake by 1,173% in Q2 2026, buying an estimated $3.8M and bringing the position to 85,756 shares worth $3.99M. The position accounts for 0.01% of the portfolio, ranked #1478.

Dmitry Balyasny first reported a position in SUPN in Q3 2016 and has held it in 12 quarters since. The position peaked at $5.83M in Q3 2017. 331 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Dmitry Balyasny held 85,756 shares of Supernus Pharmaceuticals worth $3.99M as of Q2 2026.
  • Dmitry Balyasny bought 79,018 Supernus Pharmaceuticals shares in Q2 2026, an estimated $3.8M.
  • Supernus Pharmaceuticals made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1478 holding.
  • Dmitry Balyasny first reported a position in Supernus Pharmaceuticals in Q3 2016 and has held it in 12 quarters since.
  • Dmitry Balyasny's Supernus Pharmaceuticals position peaked at $5.83M in Q3 2017.
  • 331 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.